📇 Rhumatologue · VILLEPINTE · (93) · Salarié
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Praticien-chercheur
14 articles scientifiques publiés — formation continue solide
Délais de RDV courts dans la région
78.3 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.
Influence scientifique
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
13
13 articles ont été cités au moins 13fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.
h-index
Total citations reçues
1 112
Nombre de fois où d'autres équipes ont mentionné ses publications dans leurs propres travaux.
Publications totales
38
Articles, revues et chapitres référencés dans les bases académiques internationales.
Articles influents
14
Publications ayant marqué leur domaine — chacune citée au moins 10 fois par d'autres chercheurs.
i10-index
Thématiques principales
Affiliations FR : Hôpital Jean-Verdier · Centre hospitalier Robert-Ballanger
Source : OpenAlex (CC0, OurResearch). Indicateurs académiques agrégés sur 250 M+ d'œuvres.
Articles déposés en accès libre sur l'archive ouverte des universités françaises (HAL) — gage d'activité de recherche en France.
Long term follow-up of the STOPAGO study
2024ArticleBlood
Prolonged response after TPO-RA discontinuation in primary ITP: results of a prospective multicenter study
2023ArticleBlood
Immune thrombocytopenia and pregnancy: an exposed/nonexposed cohort study
2023ArticleBlood
Clinical spectrum and therapeutic management of auto-immune myelofibrosis: a nation-wide study of 30 cases
2021ArticleHaematologica
Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome
2016ArticleHaematologica
HTLV-1-associated inflammatory myopathies: low proviral load and moderate inflammation in 13 patients from West Indies and West Africa.
2013ArticleJournal of Clinical Virology
Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).
CHI ROBERT BALLANGER
BD ROBERT BALLANGER, 93420 VILLEPINTE
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Blood · 2009
Abstract Evans syndrome (ES) is a rare disease characterized by the simultaneous or sequential development of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) and/or immune neutropenia. To better describe the characteristics and outcome of ES in adults, a survey was initiated in 2005. The data from 68 patients (60% of them women) fulfilling strict inclusion criteria for ES are reported. The mean age at time of ITP and/or AIHA onset was 52 plus or minus 33 years, both cytopenias occurred simultaneously in 37 cases (54.5%). ES was considered as “primary” in 34 patients (50%) but was associated with an underlying disorder in half of the cases, including mainly systemic lupus, lymphoproliferative disorders, and common variable immunodeficiency. All patients were given corticosteroids, but 50 of them (73%) required at least one “second-line” treatment, including splenectomy(n = 19) and rituximab (n = 11). At time of analysis, after a mean follow-up of 4.8 years, only 22 patients (32%) were in remission off treatment; 16 (24%) had died. In elderly patients, the risk of cardiovascular manifestations related to AIHA seems to be higher than the ITP-related risk of severe bleeding. In conclusion, ES is a potentially life-threatening condition that may be associated with other underlying autoimmune or lymphoproliferative disorders.
American journal of hematology · 2017
This Phase 3 multicentre randomized double‐blind and placebo‐controlled trial aimed to compare the efficacy and safety of rituximab (RTX) to placebo for treating newly diagnosed warm autoimmune hemolytic anemia (wAIHA) in adults receiving prednisone. Adults with a confirmed diagnosis of wAIHA who previously received corticosteroids for less than 6 weeks could be included. At inclusion, all patients received prednisone at a daily dose of 1 mg/kg for 2 weeks, and then tapered according to a pre‐defined recommended reduction scheme. Besides prednisone, eligible patients received 2 infusions of RTX or placebo at a fixed dose of 1,000 mg 2‐week apart. The primary endpoint was overall response rate (complete response [CR] + partial response [PR]) in an intent‐to‐treat (ITT) analysis at 1 year. A total of 32 patients (17 females [53%], mean age at inclusion 71 ± 16 years) were enrolled and randomized. In all, 27 patients were followed for at least 1 year and their data were evaluable for response. With an ITT analysis, the overall response rate at 1 year was 75% [95%CI: 47.6‐92.7] with 11 CR and 1 PR with RTX versus 31% [11.0‐58.7] (5 CR) with placebo (P = 0.032). At 2 years, 10/16 patients with RTX versus 3/16 with placebo still showed CR (P = 0.011). Overall, eight severe infections occurred during follow‐up, six with placebo and two with RTX (P = 0.39). At 2 years, six patients with placebo had died, but none with RTX (P = 0.017). Compared to placebo, RTX combined with prednisone may be effective and safe for treating newly‐diagnosed wAIHA in adults. Am. J. Hematol. 92:23–27, 2017. © 2016 Wiley Periodicals, Inc.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2016 · Case Reports
Handra-Luca A, Haddar D, Morin AS
Presse medicale (Paris, France : 1983) · 2015 · Case Reports
Maman E, Morin AS, Soussan M, Coignard H, et al.
European journal of internal medicine · 2011 · Journal Article
Javaud N, Certal Rda S, Stirnemann J, Morin AS, et al.
Medicine · 2011 · Journal Article
Mahévas M, Chiche L, Uzunhan Y, Khellaf M, et al.
Blood · 2009 · Clinical Trial
Michel M, Chanet V, Dechartres A, Morin AS, et al.
Gastroenterologie clinique et biologique · 2005 · Case Reports
Rautou PE, Corcos O, Hammel P, Cazals-Hatem D, et al.
Blood · 2023 · Observational Study
Guillet S, Loustau V, Boutin E, Zarour A, et al.
Haematologica · 2016 · Journal Article
Grimaldi-Bensouda L, Nordon C, Michel M, Viallard JF, et al.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2010 · Case Reports
Melboucy-Belkhir S, Flexor G, Stirnemann J, Morin AS, et al.
American journal of hematology · 2017 · Clinical Trial, Phase III
Michel M, Terriou L, Roudot-Thoraval F, Hamidou M, et al.
Antimicrobial agents and chemotherapy · 2002 · Journal Article
Morin AS, Poirel L, Mory F, Labia R, et al.
The Thoracic and cardiovascular surgeon · 1996 · Case Reports
Morin AM, Boyer AS, Nataf P, Gandjbakhch I
European journal of haematology · 2016 · Journal Article
Stirnemann J, Kaddouri N, Khellaf M, Morin AS, et al.
La Revue du praticien · 2007 · Case Reports
Fain O, Aras N, Morin AS, Stirnemann J